Barbara Pistilli

6.6k total citations · 1 hit paper
133 papers, 1.8k citations indexed

About

Barbara Pistilli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Barbara Pistilli has authored 133 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Barbara Pistilli's work include Advanced Breast Cancer Therapies (54 papers), HER2/EGFR in Cancer Research (44 papers) and Cancer Treatment and Pharmacology (31 papers). Barbara Pistilli is often cited by papers focused on Advanced Breast Cancer Therapies (54 papers), HER2/EGFR in Cancer Research (44 papers) and Cancer Treatment and Pharmacology (31 papers). Barbara Pistilli collaborates with scholars based in France, United States and Italy. Barbara Pistilli's co-authors include Martine Piccart, Hope S. Rugo, Mario Campone, Gabriel N. Hortobágyi, Elie Rassy, Bohuslav Melichar, Fedro A. Peccatori, Kathleen I. Pritchard, Michael Gnant and Shinzaburo Noguchi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Barbara Pistilli

119 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Gabriel N. Hortobágyi, Mario Campone et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Pistilli France	22	1.2k	818	459	443	194	133	1.8k
Laura Pizzuti Italy	23	906 0.7×	333 0.4×	454 1.0×	410 0.9×	164 0.8×	96	1.7k
Daniel Egle Austria	18	1.0k 0.8×	397 0.5×	990 2.2×	613 1.4×	59 0.3×	88	2.3k
Vicente Guillém Spain	18	1.2k 1.0×	642 0.8×	374 0.8×	394 0.9×	42 0.2×	52	2.0k
Hamdy A. Azim Egypt	19	766 0.6×	352 0.4×	230 0.5×	252 0.6×	127 0.7×	66	1.1k
Giovanna Masci Italy	21	789 0.6×	376 0.5×	471 1.0×	526 1.2×	110 0.6×	73	1.6k
J. Thaddeus Beck United States	19	1.4k 1.1×	740 0.9×	551 1.2×	619 1.4×	53 0.3×	74	2.1k
Ana C. Xavier United States	13	1.1k 0.9×	1.1k 1.4×	518 1.1×	333 0.8×	106 0.5×	51	1.8k
Andreas Trojan Switzerland	22	741 0.6×	295 0.4×	339 0.7×	151 0.3×	95 0.5×	64	1.8k
Daniel Vorobiof South Africa	18	938 0.8×	390 0.5×	153 0.3×	300 0.7×	75 0.4×	61	1.6k
Aurélie Bertaut France	24	838 0.7×	590 0.7×	357 0.8×	291 0.7×	48 0.2×	105	1.8k

Countries citing papers authored by Barbara Pistilli

Since Specialization

Citations

This map shows the geographic impact of Barbara Pistilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Pistilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Pistilli more than expected).

Fields of papers citing papers by Barbara Pistilli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Pistilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Pistilli. The network helps show where Barbara Pistilli may publish in the future.

Co-authorship network of co-authors of Barbara Pistilli

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Pistilli. A scholar is included among the top collaborators of Barbara Pistilli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Pistilli. Barbara Pistilli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pistilli, Barbara, et al.. (2025). Patritumab deruxtecan in breast cancer treatment: a drug evaluation. Future Oncology. 21(30). 3923–3934.

Lusque, Amélie, Véronique Dièras, Élise Deluche, et al.. (2024). 343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial. Annals of Oncology. 35. S359–S359. 2 indexed citations

Pistilli, Barbara, Luisa Pierotti, Cécile Vicier, et al.. (2024). 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Annals of Oncology. 35. S357–S357. 11 indexed citations

Barrios, Carlos H., Nadia Harbeck, Gabriel N. Hortobágyi, et al.. (2024). 113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Open. 9. 103101–103101. 2 indexed citations

André, Fabrice, Massimo Cristofanilli, Giuseppe Curigliano, et al.. (2024). Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1). Cancer Research. 84(9_Supplement). PO2–20. 1 indexed citations

Planchard, David, Nathalie Cozic, Marie Wislez, et al.. (2024). ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.. Journal of Clinical Oncology. 42(16_suppl). 8501–8501. 6 indexed citations

Hamilton, Erika, Patrick Neven, Barbara Pistilli, et al.. (2024). Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292. Cancer Research. 84(9_Supplement). PS12–9. 2 indexed citations

Pegram, Mark D., Carmen Calfa, Christopher S. Chen, et al.. (2024). Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 42(16_suppl). TPS1121–TPS1121. 1 indexed citations

Baldini, Capucine, Ariane Laparra, Olivier Lambotte, et al.. (2024). Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer. SHILAP Revista de lepidopterología. 5. 100061–100061. 4 indexed citations

10.

Epaillard, Nicolas, Amélie Lusque, William Jacot, et al.. (2024). Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort. ESMO Open. 9(5). 103447–103447. 3 indexed citations

11.

Epaillard, Nicolas, et al.. (2023). Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer. Cancer Treatment Reviews. 119. 102597–102597. 17 indexed citations

12.

Rassy, Elie, Ingrid Garberis, Alicia Tran-Dien, et al.. (2023). Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers. Clinical Cancer Research. 29(9). 1822–1831. 2 indexed citations

13.

Grinda, Thomas, et al.. (2023). Intracranial hypotension in a breast cancer patient treated with epidural blood patches. CNS Oncology. 12(1). CNS94–CNS94.

14.

Soldato, Davide, Julie Havas, Tracy E. Crane, et al.. (2022). Coffee and tea consumption, patient‐reported, and clinical outcomes in a longitudinal study of patients with breast cancer. Cancer. 128(19). 3552–3563. 3 indexed citations

15.

Martin, Élise, Antonio Di Meglio, Cécile Charles, et al.. (2021). Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration. JMIR Cancer. 7(1). e23927–e23927. 14 indexed citations

16.

Gbenou, Arnauld, Julie Havas, Élise Martin, et al.. (2021). Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast. 57. 43–48. 3 indexed citations

17.

Suciu, Voïchita, et al.. (2021). Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. Breast Cancer Research and Treatment. 188(2). 501–509. 24 indexed citations

18.

Giuliano, Mario, Francesco Schettini, Carla Rognoni, et al.. (2019). Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet Oncology. 20(10). 1360–1369. 119 indexed citations

19.

Rodrigues-Ferreira, Sylvie, Laetitia Fuhrmann, Magali Lacroix‐Triki, et al.. (2018). Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis. Breast Cancer Research and Treatment. 173(3). 573–583. 13 indexed citations

20.

Pistilli, Barbara, Timothy Pluard, Ander Urruticoechea, et al.. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168(2). 357–364. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact